



Kenvue Inc. (KVUE)

Updated November 12th, 2023 by Nathan Parsh

Key Metrics

Current Price:	\$19.15	5 Year CAGR Estimate:	5.5%	Market Cap:	\$37 B
Fair Value Price:	\$17.78	5 Year Growth Estimate:	3.0%	Ex-Dividend Date:	11/07/23
% Fair Value:	108%	5 Year Valuation Multiple Estimate:	-1.5%	Dividend Payment Date:	11/22/23
Dividend Yield:	4.2%	5 Year Price Target	\$21	Years Of Dividend Growth:	61
Dividend Risk Score:	C	Retirement Suitability Score:	B	Rating:	Hold

Overview & Current Events

On May 4th, 2023, Johnson & Johnson (JNJ) completed its split off of its consumer healthcare group, called Kenvue Inc. Kenvue has three segments, including Self Care, Skin Health and Beauty, and Essential Health. Self Care's product portfolio includes cough, cold, allergy, smoking cessation, and pain care products among others. Skin Health and Beauty holds products such as face, body, hair, and sun care. Essential Health contains products for women's health, wound care, oral care, and baby care. Well-known brands in Kenvue's product line up include Tylenol, Listerine, Band-Aid, Neutrogena, Nicorette, and Zyrtec. These businesses contributed approximately 17% of Johnson & Johnson's annual revenue. While Kenvue is a new, standalone business, it carries Johnson & Johnson's 61-year dividend increase streak.

On July 24th, 2023, Johnson & Johnson announced that it will offer at least 80.1% of its Kenvue stake, roughly 1.5 billion shares, in exchange for JNJ common stock. The parent company currently holds an 89.6% ownership stake in Kenvue. The exchange offer is voluntary for Johnson & Johnson investors as they can elect to exchange all, some, or none of their shares. On July 20th, 2023, Kenvue announced its first-ever quarterly dividend of \$0.20 per share to be distributed on September 7th, 2023.

On October 26th, 2023, Kenvue reported third quarter earnings results for the period ending October 1st, 2023. Revenue grew 3.4% to \$3.92 billion, which was \$10 million above estimates. Adjusted earnings-per-share of \$0.31 was in-line with expectations.

Organic sales grew 3.6% as pricing and mix were partially offset by a 3.5% decline in volume. Cold and cough were again strong while skin, health, and beauty also showed gains. Gross profit margin improved 140 basis points to 57.5%.

Kenvue also provided an updated outlook for 2023. The company now expects revenue growth to be in a range of 4.0% to 4.5% and organic growth of 5.5% to 6.0%, down from 4.5% to 5.5% and 5.5% to 6.5%, respectively. Kenvue projects adjusted earnings-per-share to be in a range of \$1.26 to \$1.28 for the year, down from \$1.26 to \$1.31 previously.

Growth on a Per-Share Basis

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2028
EPS	---	---	---	---	---	---	---	---	---	---	\$1.27	\$1.47
DPS	---	---	---	---	---	---	---	---	---	---	\$0.80	\$0.93
Shares¹	---	---	---	---	---	---	---	---	---	---	1,920	1,920

Johnson & Johnson produced annual earnings growth of 7% for the 2013 to 2022 period as the company's diversification allowed it to be one of the more stable companies in the market place. Kenvue consists of just the consumer products businesses, which were often produced the lowest levels of growth. Therefore, we expect that Kenvue will grow earnings-per-share by 3% annually through 2028.

Johnson & Johnson's dividend growth streak of 61 consecutive years is one of the longest in the market place. The company is both a Dividend King and a Dividend Aristocrat. We believe that penchant for dividend growth is in Kenvue's business DNA. The annualized dividend of \$0.80 per share represents a dividend yield of 4.2%, which is nearly three

¹ In millions of shares.

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



Kenvue Inc. (KVUE)

Updated November 12th, 2023 by Nathan Parsh

times the average of the S&P 500 Index. We also note that this yield is above Johnson & Johnson's 10-year average yield of 2.7%.

Valuation Analysis

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	Now	2028
Avg. P/E	---	---	---	---	---	---	---	---	---	---	15.1	14.0
Avg. Yld.	---	---	---	---	---	---	---	---	---	---	4.2%	4.5%

Shares of Kenvue have declined 21.5% since our July 31st, 2023 report and almost 30% since the IPO. The stock is trading at 15.1 times expected earnings-per-share for 2023. For context, Johnson & Johnson shares have an average price-to-earnings ratio of close to 19 since 2013. Countering the fact that Kenvue holds some of the industry leading brands with that its products were the lower margin businesses within the parent company, we have a target price-to-earnings ratio of 14 for the stock. This implies a headwind from multiple contraction. Therefore, valuation could reduce annual returns by 1.5% were the stock to reach our target multiple by 2028.

Safety, Quality, Competitive Advantage, & Recession Resiliency


Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2028
Payout	---	---	---	---	---	---	---	---	---	---	63%	63%

Johnson & Johnson has proven to be one of the most successful companies at navigating recessions. Though Kenvue no longer benefits from its parent company's diversification, we believe that it would prove equally effective at handling economic downturns. The company's products, such as Band-Aid and Tylenol, are needed regardless of the state of the economy as they deal directly with consumers' health and well-being. As trusted products, they would like continue to perform well even under adverse conditions.

Final Thoughts & Recommendation

After third quarter results, Kenvue is projected to offer an annual return of 5.5% through 2028, up from 0.7% previously. This return stems from 3% earnings growth and a starting yield of 4.2% that are offset by a valuation headwind. After decades as part of Johnson & Johnson, Kenvue became an independent entity early in the second quarter. The company produced a decent second quarter. While we find the legacy business to be recession-resistant and the yield to be generous, the total return profile is unattractive at the current time. We have a five-year price target of \$21, but we now view shares of Kenvue as a hold due to projected returns.

Total Return Breakdown by Year



[Click here to rate and review this research report. Your feedback is important to us.](#)

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



Kenvue Inc. (KVUE)

Updated November 12th, 2023 by Nathan Parsh

Income Statement Metrics

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
Revenue	---	---	---	---	---	---	---	---	---	---
Gross Profit	---	---	---	---	---	---	---	---	---	---
Gross Margin	---	---	---	---	---	---	---	---	---	---
D&A Exp.	---	---	---	---	---	---	---	---	---	---
Operating Profit	---	---	---	---	---	---	---	---	---	---
Operating Margin	---	---	---	---	---	---	---	---	---	---
Net Profit	---	---	---	---	---	---	---	---	---	---
Net Margin	---	---	---	---	---	---	---	---	---	---
Free Cash Flow	---	---	---	---	---	---	---	---	---	---
Income Tax	---	---	---	---	---	---	---	---	---	---

Balance Sheet Metrics

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
Total Assets	---	---	---	---	---	---	---	---	---	---
Cash & Equivalents	---	---	---	---	---	---	---	---	---	---
Acc. Receivable	---	---	---	---	---	---	---	---	---	---
Inventories	---	---	---	---	---	---	---	---	---	---
Goodwill & Int.	---	---	---	---	---	---	---	---	---	---
Total Liabilities	---	---	---	---	---	---	---	---	---	---
Accounts Payable	---	---	---	---	---	---	---	---	---	---
Long-Term Debt	---	---	---	---	---	---	---	---	---	---
Total Equity	---	---	---	---	---	---	---	---	---	---
LTD/E Ratio	---	---	---	---	---	---	---	---	---	---

Profitability & Per Share Metrics

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
Return on Assets	---	---	---	---	---	---	---	---	---	---
Return on Equity	---	---	---	---	---	---	---	---	---	---
ROIC	---	---	---	---	---	---	---	---	---	---
Shares Out.	---	---	---	---	---	---	---	---	---	---
Revenue/Share	---	---	---	---	---	---	---	---	---	---
FCF/Share	---	---	---	---	---	---	---	---	---	---

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.